KORU Medical Systems (NASDAQ:KRMD) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• KORU Medical Systems reported EPS of $0.02, beating the consensus estimate of a $0.02 loss by $0.04; quarterly revenue of $11.57 million also topped estimates.
• Revenue grew 11% to $11.6 million, while gross margin increased 5 percentage points year over year to 65.2%; the company recorded its second consecutive quarter of positive net income.
• KORU raised its 2026 revenue outlook to $48 million–$48.5 million and expects positive full-year adjusted EBITDA and year-end cash above $8 million.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.04, FiscalAI reports. The business had revenue of $11.57 million for the quarter, compared to the consensus estimate of $11.33 million. KORU Medical Systems had a negative return on equity of 10.63% and a negative net margin of 4.03%.

Here are the key takeaways from KORU Medical Systems' conference call:

• Q3 revenue grew 11% to $11.6 million, though growth slowed as expected amid international timing effects. On a normalized basis, domestic core revenue grew 10% and international core grew 23%; management expects high-teens growth in Q4.
• Profitability and margins improved: gross margin rose 500 basis points year over year to 65.2%, and the company reported its second consecutive quarter of positive net income, alongside progress in adjusted EBITDA.
• KORU raised its 2026 outlook: revenue guidance is now $48 million–$48.5 million, gross margin guidance is 63%–64%, and the company expects positive full-year adjusted EBITDA and year-end cash above $8 million.
• Commercial and product initiatives broaden potential growth: new distribution agreements in Europe and Africa, three specialty pharmacies dispensing KORU products for RYSTIGGO home administration, and progress on drug programs and the Freedom360 pump could expand reach, though several opportunities remain subject to partner timelines and regulatory review.

KORU Medical Systems Trading Down 2.2%

Shares of NASDAQ KRMD traded down $0.07 during mid-day trading on Tuesday, reaching $3.16. The company had a trading volume of 207,913 shares, compared to its average volume of 184,836. The stock has a market cap of $145.14 million, a price-to-earnings ratio of -79.00 and a beta of 0.47. KORU Medical Systems has a 52 week low of $2.86 and a 52 week high of $6.61. The business's 50-day moving average is $3.12 and its 200-day moving average is $3.96.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on KRMD shares. Weiss Ratings downgraded shares of KORU Medical Systems from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, September 29th. Zacks Research downgraded shares of KORU Medical Systems from a "strong-buy" rating to a "hold" rating in a report on Friday, October 30th. Craig Hallum reissued a "buy" rating and set a $6.00 price objective on shares of KORU Medical Systems in a research note on Thursday, August 6th. Finally, Wall Street Zen downgraded KORU Medical Systems from a "buy" rating to a "hold" rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $7.00.

Insider Buying and Selling

In related news, insider Adam Kalbermatten bought 32,000 shares of KORU Medical Systems stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average cost of $3.16 per share, with a total value of $101,120.00. Following the completion of the transaction, the insider owned 394,017 shares in the company, valued at $1,245,093.72. The trade was a 8.84% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 18.50% of the stock is owned by corporate insiders.

About KORU Medical Systems

KORU Medical Systems, Inc. develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company's products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems. KORU's principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.